BGOG-ov80/ALEPRO

A Phase II, Open-label, Multicenter Study of Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

Open
Trial drug
Abemaciclib, Letrozole
Grade
Low grade
Prior lines
1, 2, 3, 4, >4
Histology
Serous, Endometrioid Other (bv. mixed/rare)
Platin
Platinum sensitive
Platinum resistant
Phase
II

Treatment

In this study two different treatments are combined:

  • Abemaciclib (tablets, 150mg, twice daily)
  • Letrozole (tablets, 2,5mg, once daily)
     

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.